Danish medical journalHumansBreast NeoplasmsFemaleDenmarkRetrospective Studies
Real-world efficacy of tucatinib in Danish human epidermal growth factor receptor 2-positive metastatic breast cancer.
Laurits Sebastian Dahl, Ann Søegaard Knoop, Maj-Britt Jensen, Eva Harder, Jeanette Dupont Rønlev, Tobias Berg
Published: 202510.61409/A11240821
Abstract
INTRODUCTION: Tucatinib in combination with trastuzumab and capecitabine is approved for the treatment of metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer in third-line and later based on the results of the HER2CLIMB…
Preview only. Read the full abstract at the source